ArticleAnnals of medicine2025

Cost-effectiveness analysis of capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy.

Tong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.